These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30242031)

  • 1. Immune checkpoint inhibitor rechallenge in patients with immune-related myositis.
    Delyon J; Brunet-Possenti F; Leonard-Louis S; Arangalage D; Baudet M; Baroudjian B; Lebbe C; Hervier B;
    Ann Rheum Dis; 2019 Nov; 78(11):e129. PubMed ID: 30242031
    [No Abstract]   [Full Text] [Related]  

  • 2. Atypical autoimmune adverse effects with checkpoint blockade therapies.
    Friedman CF; Snyder A
    Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 4. Immune checkpoint inhibitors.
    Hui E
    J Cell Biol; 2019 Mar; 218(3):740-741. PubMed ID: 30760493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series.
    Strohbehn IA; Lee M; Seethapathy H; Chute D; Rahma O; Guidon A; Neilan TG; Zlotoff DA; Okin D; Rengarajan M; Reynolds K; Sise ME
    Am J Kidney Dis; 2020 Aug; 76(2):299-302. PubMed ID: 32417401
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune checkpoint inhibitors: a new era for esophageal cancer.
    Zou LQ; Yang X; Li YD; Zhu ZF
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):731-738. PubMed ID: 31424306
    [No Abstract]   [Full Text] [Related]  

  • 7. Endocrine sequelae of immune checkpoint inhibitors.
    Ntali G; Kassi E; Alevizaki M
    Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
    Brahmer JR; Lacchetti C; Schneider BJ; Atkins MB; Brassil KJ; Caterino JM; Chau I; Ernstoff MS; Gardner JM; Ginex P; Hallmeyer S; Holter Chakrabarty J; Leighl NB; Mammen JS; McDermott DF; Naing A; Nastoupil LJ; Phillips T; Porter LD; Puzanov I; Reichner CA; Santomasso BD; Seigel C; Spira A; Suarez-Almazor ME; Wang Y; Weber JS; Wolchok JD; Thompson JA;
    J Clin Oncol; 2018 Jun; 36(17):1714-1768. PubMed ID: 29442540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint blockade after kidney transplantation.
    Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
    Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
    Guerrero E; Johnson DB; Bachelot A; Lebrun-Vignes B; Moslehi JJ; Salem JE
    Eur J Cancer; 2019 May; 113():10-13. PubMed ID: 30954881
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

  • 12. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
    Patel JD; Chmura SJ
    Cancer; 2018 Jul; 124(14):2878-2880. PubMed ID: 29906817
    [No Abstract]   [Full Text] [Related]  

  • 13. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
    Kennedy LC; Bhatia S; Thompson JA; Grivas P
    J Natl Compr Canc Netw; 2019 Jun; 17(6):750-757. PubMed ID: 31200356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
    Zahavi DJ; Weiner LM
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
    Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
    Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
    Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
    Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In brief: Avelumab (Bavencio) for metastatic merkel cell carcinoma.
    Med Lett Drugs Ther; 2017 Jul; 59(1521):e120. PubMed ID: 28699934
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.